Combined measurement of serum tumor markers in patients with hepatocellular carcinoma

Table 1 The serum levels of AFP, AFU and SA among patients in the three groups (x ± s)

Groups	AFP (μg/L)	AFU (nkat/L)	SA (mg/L)
Control	10.2 ± 9.8	106.0 ± 36.5	513.7 ± 57.8
Cirrhosis	14.4 ± 9.0	126.8 ± 52.1	522.7 ± 70.5
HCC	71.7 ± 38.8bd	284.5 ± 102.6bd	636.7 ± 76.6bd

^bP < 0.01, compared with controls,

^dP < 0.01, compared with cirrhosis.

Table 2 Positive rates of AFP, AFU and SA among the three groups

Groups	AFU		AFU		SA
	n	(%)	n	(%)	n	(%)
Controls	1	(3.3)	1	(3.3)	2	(6.7)
Cirrhosis	2	(6.7)	4	(13.3)	5	(16.7)
HCC	21	(70.0)	23	(76.7)	21	(70.0)

Table 3 Significance of AFP, AFU and SA (%)

	AFP	AFU	SA
Sensitivity	70.0 (21/30)	76.7 (23/30)	70.0 (21/30)
Specificity	95.0 (57/60)	91.7 (55/60)	88.3 (53/60)
Positive predictive value	87.5 (21/24)	82.1 (23/28)	75.0 (21/28)
Negative predictive value	86.4 (57/66)	88.7 (55/62)	85.5 (53/62)
Accuracy	86.7 (78/90)	86.7 (78/90)	82.2 (74/90)

Table 4 Results of combined measurement of serum AFP, AFU and SA in the three groups

Groups	Postivity
	n	%
Controls	0	0.0
Cirrhosis	1	3.3
HCC	26	86.7

Table 5 Comparison between AFP and AFU in patients with HCC

AFP	AFU
	Positive	Negative	Total
Positive	16	5	21
Negative	7	2	9
Total	23	7	30